OrthoPediatrics Q2 revenue $70.5M (+15% YoY), raises FY2026 guidance to $265-269M

ORTHOPEDIATRICS CORP

Q2 2026 revenue $70.5M, up 15% YoY; domestic +14%, international +22%.
Trauma & Deformity revenue $52.6M (+26% YoY); Scoliosis $16.9M (-9% YoY).
Net loss $7.2M ($0.30/share); adjusted EBITDA $6.8M vs $4.1M YoY.
Free cash flow usage improved 78% to $3.1M; cash $47.9M at quarter end.
Raised FY2026 revenue guidance to $265-269M; expects breakeven FCF in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.